Tags

Type your tag names separated by a space and hit enter

Ebastine in the Treatment of Allergic Rhinitis and Urticaria: 30 Years of Clinical Studies and Real-World Experience.
J Investig Allergol Clin Immunol. 2020; 30(3):156-168.JI

Abstract

Histamine, acting predominantly via the H1-receptor, is an important mediator of the symptoms of allergy. H1-antihistamines, which stabilize the receptor in its inactive form, are the treatment of choice for some chronic allergic conditions. Ebastine is a well-established secondgeneration oral H1-antihistamine that is administered once daily at a dose of 10-20 mg and is available both as a standard tablet and as a fast-dissolving tablet that disintegrates in the mouth. Ebastine has been shown to relieve symptoms in patients with allergic rhinitis or urticaria in multiple clinical trials. In addition to its antihistamine effects, the drug has modulating effects on the allergic inflammatory process, thus potentially explaining its beneficial effect on nasal obstruction in some patients. Ebastine is generally well tolerated at recommended doses and is one of the lowest-risk antihistamines with respect to adverse cognitive/psychomotor effects, as confirmed by decades of pharmacovigilance. New long-term data confirm its efficacy and tolerability during up to 1 year of treatment in patients with chronic urticaria.

Authors+Show Affiliations

Department of Allergy, Fundación Jimenez Diaz, Madrid. CIBERES, Instituto Carlos III Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30977465

Citation

Sastre, J. "Ebastine in the Treatment of Allergic Rhinitis and Urticaria: 30 Years of Clinical Studies and Real-World Experience." Journal of Investigational Allergology & Clinical Immunology, vol. 30, no. 3, 2020, pp. 156-168.
Sastre J. Ebastine in the Treatment of Allergic Rhinitis and Urticaria: 30 Years of Clinical Studies and Real-World Experience. J Investig Allergol Clin Immunol. 2020;30(3):156-168.
Sastre, J. (2020). Ebastine in the Treatment of Allergic Rhinitis and Urticaria: 30 Years of Clinical Studies and Real-World Experience. Journal of Investigational Allergology & Clinical Immunology, 30(3), 156-168. https://doi.org/10.18176/jiaci.0401
Sastre J. Ebastine in the Treatment of Allergic Rhinitis and Urticaria: 30 Years of Clinical Studies and Real-World Experience. J Investig Allergol Clin Immunol. 2020;30(3):156-168. PubMed PMID: 30977465.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ebastine in the Treatment of Allergic Rhinitis and Urticaria: 30 Years of Clinical Studies and Real-World Experience. A1 - Sastre,J, Y1 - 2019/04/12/ PY - 2019/4/13/pubmed PY - 2021/4/10/medline PY - 2019/4/13/entrez KW - Allergic rhinitis KW - Antihistamines KW - Ebastine KW - H1-receptor antagonists KW - Urticaria SP - 156 EP - 168 JF - Journal of investigational allergology & clinical immunology JO - J Investig Allergol Clin Immunol VL - 30 IS - 3 N2 - Histamine, acting predominantly via the H1-receptor, is an important mediator of the symptoms of allergy. H1-antihistamines, which stabilize the receptor in its inactive form, are the treatment of choice for some chronic allergic conditions. Ebastine is a well-established secondgeneration oral H1-antihistamine that is administered once daily at a dose of 10-20 mg and is available both as a standard tablet and as a fast-dissolving tablet that disintegrates in the mouth. Ebastine has been shown to relieve symptoms in patients with allergic rhinitis or urticaria in multiple clinical trials. In addition to its antihistamine effects, the drug has modulating effects on the allergic inflammatory process, thus potentially explaining its beneficial effect on nasal obstruction in some patients. Ebastine is generally well tolerated at recommended doses and is one of the lowest-risk antihistamines with respect to adverse cognitive/psychomotor effects, as confirmed by decades of pharmacovigilance. New long-term data confirm its efficacy and tolerability during up to 1 year of treatment in patients with chronic urticaria. SN - 1018-9068 UR - https://www.unboundmedicine.com/medline/citation/30977465/Ebastine_in_the_Treatment_of_Allergic_Rhinitis_and_Urticaria:_30_Years_of_Clinical_Studies_and_Real_World_Experience_ DB - PRIME DP - Unbound Medicine ER -